China Human Vaccine Industry Report, 2017-2021
  • Jul.2017
  • Hard Copy
  • USD $3,000
  • Pages:130
  • Single User License
    (PDF Unprintable)       
  • USD $2,800
  • Code: ZLC052
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,400
  • Hard Copy + Single User License
  • USD $3,200

The human vaccine industry presented the following main characteristics in 2016 in China:

1. Lot release volume of human vaccines declined.
Affected by the illegal vaccine case in Mar 2016 in Shandong, the country’s lot release volume of human vaccines came to 553.6 million doses through the year 2016, down 3.8% over the previous year. The lot release volume of ten vaccines (Hepatitis B vaccine, Diphtheria, Tetanus and acellular Pertussis combined vaccine (adsorbed), rabies vaccine, Japanese encephalitis vaccine, poliomyelitis vaccine, meningococcal vaccine, measles and rubella combined attenuated live vaccine, MMR combined attenuated live vaccine, influenza vaccine, and Hepatitis A Vaccine) was relatively higher, totaling 467.2 million doses, 84.4% of the country’s total, a year-on-year 1.4% drop.

2. The industry was highly concentrated.
The Chinese human vaccine market had been highly concentrated, primarily dominated by Beijing Tiantan Biological Products, Chengdu Institute of Biological Products, Shanghai Institute of Biological Products, Lanzhou Institute of Biological Products, Wuhan Institute of Biological Products, and Changchun Institute of Biological Products under China National Biotec Group Company Limited. In 2016, China National Biotec Group accounted for 52.6% of the country’s lot release volume of human vaccines, compared with a small fraction of market share for Liaoning Chengda Biotechnology, Changsheng Bio-technology, Shenzhen Kangtai Biological Products, Chongqing Zhifei Biological Products, Beijing Minhai Biotechnology, Walvax Biotechnology, Changchun BCHT Biotechnology, Hualan Biological Engineering, Zhejiang Tianyuan Bio-Pharmaceutical, and Sinovac Biotech.


3. Vaccine enterprises scaled up R&D efforts.
Major Chinese vaccine enterprises have intensified their efforts for R&D in order to enhance overall competitiveness in recent years. Walvax Biotechnology has started HPV-2 industrialization project and is expected to launch the product in 2019, and meanwhile has put its 13-valent pneumococcal combined vaccine in phase III clinical trial and is predicted to bring the product to the market in 2018 or 2019. Launching of new vaccines will make the company more competitive.

4. Two-child policy, population aging, and new vaccines were drivers of the industry.
Along with full implementation of the two-child policy in Oct 2015, the country’s newborns increased sharply to 17.86 million in 2016 and will remain above 18 million each year over the next five years. Meanwhile, the population aged 60 and over reached 230.9 million by the end of 2016 and is expected to hit 245.3 million by 2021. In addition, some domestic enterprises have set about developing new vaccines like HPV vaccine and 13-valent pneumococcal vaccine which are expected to be available on the market in 2018 or 2019.

Pushed by the two-child policy, population aging, and launching of new vaccines, the vaccine industry in China will grow rapidly with an estimated market size of up to RMB31.2 billion in 2021.

China Human Vaccine Industry Report, 2017-2021 highlights the following:
20120114.gifHuman vaccine industry in China (operating environment, status quo, market demand, market size, circulation channel, import & export, competitive landscape, development trends, etc.);
20120114.gifAnalysis on Chinese human vaccine market segments(like Hepatitis B Vaccine, Meningococcal Vaccine, Hepatitis A vaccine, Influenza Vaccine, Hib Vaccine, Rabies Vaccine, Varicella Vaccine, Pneumococcal Vaccines, DTP Vaccine, Poliomyelitis Vaccine, Hepatitis E Vaccine), including market demand, lot release volume, competitive landscape, etc.;
20120114.gif19 local vaccine enterprises (operation, gross margin, major customers, R&D and investment, development and forecast, etc.).

1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain

2. China Human Vaccine Industry Development Analysis
2.1 Operating Environment
2.1.1 International Market
2.1.2 Policy Environment
2.1.3 Biopharmaceutical Market
2.2 Status Quo
2.3 Supply & Demand
2.4 Market Size
2.5 Circulation Channel
2.6 Import & Export
2.6.1 Import
2.6.2 Export
2.6.3 Average Price
2.7 Competition Pattern
2.8 Development Trend
2.8.1 Vaccine for Cervical Cancer Prevention is expected to be launched in China 
2.8.2 Domestic Pneumococcal 13-valent Conjugate Vaccine is Expected to be launched 
2.8.3 Two-child Policy Favorable to Industry Development
2.8.4 Aging population propel industry development to some extent
2.8.5 Industry scale rises stably 

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Supply & Demand
3.1.2 Lot Release Volume
3.1.3 Competition Pattern
3.2 Meningococcal Vaccine
3.2.1 Supply & Demand
3.2.2 Lot Release Volume
3.2.3 Competition Pattern
3.3 Hepatitis A Vaccine
3.3.1 Supply & Demand
3.3.2 Lot Release Volume
3.3.3 Competition Pattern
3.4 Influenza Vaccine
3.4.1 Supply & Demand
3.4.2 Lot Release Volume
3.4.3 Competition Pattern
3.5 Hib Vaccine
3.5.1 Supply & Demand
3.5.2 Lot Release Volume
3.5.3 Competition Pattern
3.5.4 Market Forecast
3.6 Human Rabies Vaccine
3.6.1 Supply & Demand
3.6.2 Lot Release Volume
3.6.3 Competition Pattern
3.7 Varicella Vaccine
3.7.1 Supply & Demand
3.7.2 Lot Release Volume
3.7.3 Competition Pattern
3.8 Pneumococcal Vaccines
3.8.1 Supply & Demand
3.8.2 Lot Release Volume
3.8.3 Competition Pattern
3.9 DTP Vaccine
3.9.1 Supply & Demand
3.9.2 Lot Release Volume
3.9.3 Competition Pattern
3.10 Poliomyelitis Vaccine
3.10.1 Supply & Demand
3.10.2 Lot Release Volume
3.10.3 Competition Pattern
3.11 Hepatitis E Vaccine
3.11.1 Supply & Demand
3.11.2 Lot Release Volume
3.11.3 Competition Pattern

4. Major Vaccine Manufacturers in China
4.1 China National Biotec Group
4.1.1 Profile
4.1.2 Beijing Tiantan Biological Products Co., Ltd
4.1.3 Chengdu Institute of Biological Products Co., Ltd.
4.1.4 Shanghai Institute of Biological Products Co., Ltd.
4.1.5 Wuhan Institute of Biological Products Co., Ltd.
4.1.6 Lanzhou Institute of Biological Products Co., Ltd.
4.1.7 Changchun Institute of Biological Products Co., Ltd.
4.2 Beijing Tiantan Biological Products Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D Cost and Investment 
4.2.6 Clients
4.2.7 Vaccine Business
4.2.8 Development and Prospects
4.3 Hualan Biological Engineering Inc.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 R&D Cost and Investment n
4.3.5 Clients
4.3.6 Vaccine Business
4.3.7 Development and Prospects
4.4 Chongqing Zhifei Biological Products Co., Ltd.  
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Major Clients 
4.4.6 R&D Cost and Investment
4.4.7 Development and Prospects
4.5 Walvax Biotechnology Co, Ltd.   
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin 
4.5.5 Major Clients 
4.5.6 R&D Cost and Investment
4.5.7 Vaccine Business
4.5.8 Development and Prospects
4.6 Liaoning Cheng Da Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Clients
4.6.6 R&D Cost and Investment  
4.6.7 Development and Prospects
4.7 Shenzhen Kangtai Biological Products Co., Ltd.  
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 Clients
4.7.6 R&D Cost and Investment  
4.7.7 Development and Prospects
4.8 Changchun Changsheng Life Sciences Limited
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 R&D Cost and Investment  
4.8.5 Development and Prospects
4.9 Sinovac Biotech Ltd.   
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Sinovac Biotech (Beijing)
4.10 Changchun BCHT Biotechnology Co. Ltd.
4.10.1 Profile
4.10.2 Operation
4.10.3 Development Dynamics
4.11 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. 
4.11.1 Profile
4.11.2 Operation
4.12 Dalian Hissen Bio-Pharm Co., Ltd.  
4.12.1 Profile
4.13 NCPC GeneTech Biotechnology Development Co., Ltd. 
4.13.1 Profile
4.13.2 Operation
4.14 Dalian Aleph Biomedical Co., Ltd. 
4.14.1 Profile
4.14.2 Development Dynamics
4.15 Beijing Minhai Biotechnology Co., Ltd. 
4.15.1 Profile
4.15.2 Operation
4.16 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
4.16.1 Profile
4.16.2 Operation
4.17 Other Enterprises
4.17.1 Jiangsu SimcereVaxtec Bio-pharmaceutical Co., Ltd.
4.17.2 Xiamen Innovax Biotech CO., LTD. 
4.17.3 Convac Biotechnology Co., Ltd.
Classification of Vaccines
Vaccine Industry Chain
Global Human Vaccine Market Size, 2010-2016
Global Human Vaccine Market Size, 2016-2021E
Revenue of Top 5 Vaccine Companies, 2008-2016
Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005- 2015
Policies in Vaccine Industry, 2016-2017
Gross Industrial Output Value of China Biopharmaceutical Industry, 2008-2016
Gross Industrial Output Value of China Biopharmaceutical Industry, 2016-2021E
EPI Human Vaccine Varieties in China
Lot Release Volume of Human Vaccine in China, 2013-2017 
Top10 Human Vaccines by Lot Release Volume in China, 2015-2016
Main Human Vaccine Varieties and Producers Granted Permit for Lot Release in China, 2016
Provinces Completing Online Publicity of Vaccine Procurement in China by the End of Mar 2017
China Human Vaccine Market Size, 2010-2016
Import Volume and Value of Human Vaccine in China, 2010-2017
China’s Human Vaccine Import Volume and Value by Country, 2016
Export Volume and Value of Human Vaccine in China, 2010-2017
Top 10 Countries/Regions of China Human Vaccine Export
Average Unit Export/Import Price of Human Vaccine in China, 2010-2017
Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2016
Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2017H1
Vaccine Lot Release Volume of Major Vaccine Enterprises in China, 2015-2017
Lot Release Volume of Vaccines in China by Enterprise, 2016
Vaccine Revenue of Major Human Vaccine Enterprises in China, 2013-2016
Market Share of Human Vaccine Industry in China by Enterprise, 2016
R&D Projects and Progress of Major Vaccine Enterprises in China by the End of 2016
Morbidity of Cervical Cancer Worldwide
Global HPV Vaccines
Global HPV Vaccine Market Size, 2006-2015
Shanghai Zerun Biotechnology’s Progress in R&D of HPV Vaccine 
China’s Newborns, 2015-2021E
Population Aged 60 and Over in China, 2009-2021E
Chinese Vaccine Market Size, 2016-2021E
Hepatitis B Morbidity and Mortality in China, 2013-2016
Lot Release Volume of Hepatitis B Vaccine in China, 2015-2017
Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2015-2017
Lot Release Volume of Major Hepatitis B Vaccine Companies in China, 2015-2017
Share of Major Hepatitis B Vaccine Companies by Lot Release Volume in China, 2015-2017
Meningitis Morbidity and Mortality in China, 2013-2016
Meningococcal Vaccines Lot Release Volume in China, 2015-2017
Meningococcal Vaccines Lot Release Volume in China by Type, 2015-2017
Lot Release Volume of Major Meningococcal Vaccines Companies in China, 2015-2017
Share of Major Meningococcal Vaccines Companies by Lot Release Volume in China, 2015-2017
Hepatitis A Morbidity and Mortality in China, 2013-2016
Lot Release Volume of Hepatitis A Vaccine in China, 2015-2017
Lot Release Volume of Major Hepatitis A Vaccine Companies in China, 2015-2017
Share of Major Hepatitis A Vaccine Companies by Lot Release Volume in China, 2015-2017
H7N9 Influenza Morbidity and Mortality in China, 2013-2016
Lot Release Volume of Influenza Vaccine in China, 2015-2016
Lot Release Volume of Major Influenza Vaccine Companies in China, 2015-2016
Share of Major Influenza Vaccine Companies by Lot Release Volume in China, 2015-2016
Lot Release Volume of Hib Vaccine in China, 2015-2017
Lot Release Volume of Major Hib Vaccine Companies in China, 2015-2017
Share of Major Hib Vaccine Companies by Lot Release Volume in China, 2015-2017
Rabies Morbidity and Mortality in China, 2013-2016
Lot Release Volume of Human Rabies Vaccine in China, 2015-2017
Lot Release Volume of Major Human Rabies Vaccine Companies in China, 2015-2017
Share of Major Human Rabies Vaccine Companies by Lot Release Volume in China, 2015-2017
Lot Release Volume of Varicella Vaccine in China, 2015-2017
Lot Release Volume of Major Varicella Vaccine Companies in China, 2015-2017
Share of Major Varicella Vaccine Companies by Lot Release Volume in China, 2015-2017
Lot Release Volume of Pneumococcal Vaccines in China, 2015-2017
Lot Release Volume of Major Pneumococcal Vaccines Companies in China, 2015-2017
Share of Major Pneumococcal Vaccine Companies by Lot Release Volume in China, 2015-2017
Pertussis Morbidity and Mortality in China, 2012-2016
Neonatal Tetanus Morbidity and Mortality in China, 2012-2016
Lot Release Volume of DTP Vaccine in China, 2015-2017
Lot Release Volume of Major DTP Vaccine Companies in China, 2015-2017
Share of Major DTP Vaccine Companies by Lot Release Volume in China, 2015-2017
Poliomyelitis Morbidity and Mortality in China, 2011-2016
Lot Release Volume of Poliomyelitis Vaccine in China, 2015-2017
Lot Release Volume of Major Poliomyelitis Vaccine Companies in China, 2015-2017
Share of Major Poliomyelitis Vaccine Companies by Lot Release Volume in China, 2015-2017
Hepatitis E Morbidity and Mortality in China, 2012-2016
Lot Release Volume of Hepatitis E Vaccine in China, 2015-2016
Lot Release Volume of Major Hepatitis E Vaccine Companies in China, 2015-2016
Vaccine Varieties of Chengdu Institute of Biological Products
Vaccine Lot Release Volume Breakdown of Chengdu Institute of Biological Products by Product, 2015-2017
Vaccine Varieties of Shanghai Institute of Biological Products
Operation of Shanghai Institute of Biological Products, 2013-2016
Vaccine Lot Release Volume Breakdown of Shanghai Institute of Biological Products by Product, 2015-2017
Vaccine Lot Release Volume Breakdown of Wuhan Institute of Biological Products by Product, 2015-2017
Vaccine Lot Release Volume Breakdown of Lanzhou Institute of Biological Products by Product, 2015-2017
Vaccine Lot Release Volume Breakdown of Changchun Institute of Biological Products by Product, 2015-2017
Revenue and Net Income of Beijing Tiantan Biological Products, 2013-2017
Revenue Breakdown of Beijing Tiantan Biological Products by Product, 2013-2016
Revenue Structure of Beijing Tiantan Biological Products by Product, 2013-2016
Revenue Breakdown of Beijing Tiantan Biological Products by Region, 2013-2016
Revenue Structure of Beijing Tiantan Biological Products by Region, 2013-2016
Gross Margin of Beijing Tiantan Biological Products by Product, 2013-2016
R&D Costs and % of Total Revenue of Beijing Tiantan Biological Products, 2013-2016
Main R&D Projects of Beijing Tiantan Biological Products as of the end of 2016
Beijing Tiantan Biological Products’ Revenue from Top5 Customers and % of Total Revenue, 2012-2016
Vaccine Revenue and Percentage of Beijing Tiantan Biological Products, 2013-2016
Output & Sales Volume of Major Vaccine Products of Beijing Tiantan Biological Products, 2016
Bidding Status of Beijing Tiantan Biological Products in Centralized Procurement Bidding, 2016
Revenue and Operating Income of Beijing Tiantan Biological Products, 2016-2021E
Revenue and Net Income of Hualan Biological Engineering, 2013-2017
Revenue Breakdown of Hualan Biological Engineering by Sector, 2013-2016
Revenue Structure of Hualan Biological Engineering by Sector, 2013-2016
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2016
Hualan Biological Engineering’s Revenue from Top5 Customers and % of Total Revenue, 2013-2016
Output & Sales Volume, Inventory of Hualan Biological Engineering, 2013-2016
Vaccine Revenue and Percentage of Hualan Biological Engineering, 2013-2016
Major Products and Application of Chongqing Zhifei Biological Products
Major Subsidiaries of Chongqing Zhifei Biological Products
Revenue and Net Income of Chongqing Zhifei Biological Products, 2012-2017
Revenue Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2016
Lot Release Volume Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2016
Revenue Breakdown of Chongqing Zhifei Biological Products by Region, 2014-2016
Gross Margin of Chongqing Zhifei Biological Products by Product, 2013-2016
Chongqing Zhifei Biological Products’ Revenue from Top5 Customers and % of Total Revenue, 2011-2016
R&D Costs and % of Total Revenue of Chongqing Zhifei Biological Products, 2011-2016
Projects under Registration Process of Chongqing Zhifei Biological Products, 2016
Progress of Preclinical Projects of Chongqing Zhifei Biological Products by the end of 2016
Revenue and Operating Income of Chongqing Zhifei Biological Products, 2016-2021E
Revenue and Net Income of Walvax Biotechnology, 2013-2017
Revenue Breakdown of Walvax Biotechnology by Product, 2014-2016
Revenue Breakdown of Walvax Biotechnology by Region, 2014-2016
Gross Margin of Walvax Biotechnology by Product, 2013-2016
Walvax Biotechnology’s Revenue from Top5 Customers and % of Total Revenue, 2015-2016
R&D Costs and % of Total Revenue of Walvax Biotechnology, 2013-2016
Progress of Products under Registration Declaration of Walvax Biotechnology as of the end of Mar.2017
Output & Sales Volume, Inventory of Walvax Biotechnology, 2014-2016
Lot Release Volume of Walvax Biotechnology, 2014-2016
Revenue and Operating Income of Walvax Biotechnology, 2016-2021E
Revenue and Net Income of Liaoning Chengda, 2013-2016
Revenue Breakdown of Liaoning Chengda by Sector, 2013-2016
Revenue Structure of Liaoning Chengda by Sector, 2013-2016
Gross Margin of Liaoning Chengda, 2013-2016
Liaoning Chengda’s Revenue from Top5 Customers and % of Total Revenue, 2015-2016
R&D Costs and % of Total Revenue of Liaoning Chengda, 2014-2016
Revenue and Net Income of Liaoning Chengda Biotechnology, 2016-2021E
Capacity, Output & Sales Volume of Shenzhen Kangtai Biological Products, 2013-2016 Revenue and Net Income of Shenzhen Kangtai Biological Products, 2013-2017
Revenue Breakdown of Shenzhen Kangtai Biological Products by Product, 2015-2016
Lot Release Volume and Percentage of Shenzhen Kangtai Biological Products, 2015-2016
Revenue Breakdown of Shenzhen Kangtai Biological Products by Region, 2015-2016
Gross Margin of Shenzhen Kangtai Biological Products, 2013-2016
Shenzhen Kangtai Biological Products’ Revenue from Top5 Customers and % of Total Revenue, 2014-2016
R&D Costs and % of Total Revenue of Shenzhen Kangtai Biological Products, 2013-2016
IPO Fund-Rasing Projects of Shenzhen Kangtai Biological Products
Revenue and Net Income of Shenzhen Kangtai Biological Products, 2016-2021E
Equity Structure of Changchun Changsheng Life Sciences
Revenue and Net Income of Changchun Changsheng Life Sciences, 2014-2017
Output & Sales Volume, Inventory of Changchun Changsheng Life Sciences, 2014-2016
Revenue Breakdown of Changchun Changsheng Life Sciences by Product,2014-2016 Revenue Structure of Changchun Changsheng Life Sciences by Product, 2014-2016 Revenue Breakdown of Changchun Changsheng Life Sciences by Region, 2014-2016 Revenue Structure of Changchun Changsheng Life Sciences by Region, 2014-2016
R&D Costs and % of Total Revenue of Changchun Changsheng Life Sciences, 2014-2016
Progress of Projects under R&D of Changchun Changsheng Life Sciences as of the end of 2016
Revenue and Net Income of Changchun Changsheng Life Sciences, 2016-2021E
Revenue and Net Income of Sinovac Biotech, 2013-2016
Revenue Breakdown of Sinovac Biotech by Product, 2013-2016
Financial Indices of Sinovac Biotech, 2015-2016
Financial Indices of Changchun BCHT Biotechnology, 2014-2016
Equity Structure of Zhejiang Tianyuan Bio-Pharmaceutical
Vaccine Products of Zhejiang Tianyuan Bio-Pharmaceutical
Revenue and Net Income of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2016
Financial Indices of Zhejiang Tianyuan Bio-Pharmaceutical, 2014-2016
Equity Structure of Dalian Aleph Biomedical
Financial Indices of Beijing Minhai Biotechnology, 2015-2016
Total Assets and Revenue of Shenzhen Sanofi Pasteur Biological Products, 2016
Development Course of Xiamen Innovax Biotech

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号